Analyst's Perspective December 2015 - Why the US Pays More for Drugs / Inside Story on Wearable Electronics / The Spreading Z...
10 February 2016 - 11:40PM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/7xm6bl/vital_signs_the)
has announced the addition of the "Vital Signs The Analyst's
Perspective - December 2015 Issue" report to their offering.
This issue of Vital Signs discusses why the US pays more than
other countries for drugs, the inside story on wearable
electronics, the spreading Zika virus, and soaring US drug
costs.
Key Findings:
- Germany was the first EU country to institute reference
pricing. At first it was based on the class of drug, but has
evolved to a system of therapeutic comparability, looking at active
ingredients, therapeutically comparable active ingredients, and
comparable pharmacological profiles.
- In Norway, the state-run health system, in addition to looking
at reference country pricing, bargains with the drug company,
requesting proof of the drug's value in comparison to the existing
marketed therapeutics. In Norway, the state pays for most
prescription drugs, though patients sometimes have co-pay
requirements.
- In Canada, reference pricing was introduced for five drug
classes, which represent the largest portion of the national drug
budget, including NSAIDs, histamine-2 receptor antagonists, oral
nitrates, ACE inhibitors, and calcium channel blocker.
For more information visit
http://www.researchandmarkets.com/research/7xm6bl/vital_signs_the
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160210005800/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Pharmaceuticals